ASOP: Assessing Ventilator Safety in Patients on Pressure-Support Ventilation

Sponsor
Duke University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05125952
Collaborator
(none)
20
1
1
10.4
1.9

Study Details

Study Description

Brief Summary

ASOP is a prospective cohort study comparing three methods for assessing risk of self-induced lung injury in patients with acute respiratory failure being managed with pressure-support ventilation. We will describe the relationship between three different assessment methods for risk of self-induced lung injury and compare them to a gold standard measurement.

Condition or Disease Intervention/Treatment Phase
  • Device: Viasys Avea Ventilator
  • Device: Philips Respironics NM3 device
  • Device: Servo U ventilator
  • Device: Vyaire SmartCath adult nasogastric tube with Esophageal balloon
N/A

Detailed Description

Ventilator-induced lung injury (VILI) is known to cause significant morbidity and mortality in patients with acute respiratory failure. Most studies on VILI have involved the effects of inappropriate (often excessive) mechanical ventilator settings. More recently, it has been noted that similar lung damage can be caused by large, patient generated, uncontrolled tidal volumes and driving pressures, which has been termed "self-induced lung injury," or SILI.

Pressure-support ventilation (PSV) is a common mechanical ventilation mode often used in patients with active inspiratory efforts to help reduce patient inspiratory work and improve comfort. PSV effectively allows spontaneously breathing patients to determine their breath flow-rate and breath duration, eliminating flow and cycle dyssynchrony. However, pressure support ventilation does not allow for physicians to control tidal volume or driving pressure. The risk of SILI may thus be increased with PSV.

Several different methods have been proposed to address these challenges. However, to date none of these methods have been compared to assess for concordance in their ability to indicate an increased risk of self-induced lung injury. ASOP is a prospective cohort study comparing three methods for assessing risk of self-induced lung injury in patients with acute respiratory failure being managed with pressure-support ventilation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Assessing Ventilator Safety in Patients on Pressure-Support Ventilation
Actual Study Start Date :
Feb 8, 2022
Anticipated Primary Completion Date :
Oct 31, 2022
Anticipated Study Completion Date :
Dec 21, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Acute Respiratory Failure

Patients with acute respiratory failure managed with pressure-support ventilation.

Device: Viasys Avea Ventilator
Measuring dynamic airway driving pressure and static airway driving pressure during pressure support breath, and static airway driving pressure during a volume control breath. Measuring airway occlusion pressure during pressure support breath.

Device: Philips Respironics NM3 device
Measuring static airway driving pressure during pressure support breath

Device: Servo U ventilator
Measuring static airway driving pressure and p0.1 during pressure support breath.

Device: Vyaire SmartCath adult nasogastric tube with Esophageal balloon
Measuring static and dynamic esophageal driving pressure during pressure support breath, and esophogeal pressure change during airway occlusion maneuver.

Outcome Measures

Primary Outcome Measures

  1. Respiratory System Driving Pressure measure by Servo Ventilator (DPrs-servo) [Study day 1]

    Driving pressure in centimeters of water measured with inspiratory hold on Servo Ventilator in pressure-support ventilation.

  2. Respiratory System Driving Pressure measure by Respironics NM3 device (DPrs-NM3) [Study day 1]

    Driving pressure in centimeters of water measured with Phillips Respironics NM3 device in pressure-support ventilation.

  3. Airway Occlusion Test (AOC) [Study day 1]

    Maximum negative airway pressure in centimeters of water during an airway occlusion maneuver.

  4. Respiratory System Driving Pressure measured during volume control breath. [Study day 1]

    Airway driving pressure in centimeters of water measured with inspiratory hold in volume control/assist control.

  5. Transpulmonary Driving pressure measured during volume control breath. [Study day 1]

    Transpulmonary driving pressure in centimeters of water measured via esophageal balloon with inspiratory hold in volume control/assist control.

Secondary Outcome Measures

  1. Duration of mechanical ventilation [Index hospitalization (up to 28 days)]

    Number of days receiving mechanical ventilation

  2. Duration of intensive care unit admission [Index hospitalization (up to 28 days)]

    Number of days admitted to intensive care unit

  3. Duration of hospital admission [Index hospitalization (up to 28 days)]

    Number of days admitted to hospital

  4. Ventilator Free Days [Index hospitalization (up to 28 days)]

    Number of days free from mechanical ventilation

  5. In-hospital survival [Index hospitalization (up to 28 days)]

    Survival to discharge

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patients age ≥18 years with acute respiratory failure receiving invasive mechanical ventilation

  • Managed in pressure-support mode of ventilation

Exclusion Criteria:
  • Actively undergoing a spontaneously awakening trial or SAT

  • Patient or surrogate is unable to provide informed consent

  • Currently pregnant

  • Currently incarcerated

  • Acute exacerbation of an obstructive lung disease

  • Known esophageal varices or any other condition for which the attending physician deems an orogastric catheter to be unsafe

  • Esophageal, gastric or duodenal surgical procedures within the last 6 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 Duke University Hospital Durham North Carolina United States 27710

Sponsors and Collaborators

  • Duke University

Investigators

  • Principal Investigator: Neil R MacIntyre, MD, Professor of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Duke University
ClinicalTrials.gov Identifier:
NCT05125952
Other Study ID Numbers:
  • Pro00106860
First Posted:
Nov 18, 2021
Last Update Posted:
Feb 10, 2022
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Duke University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 10, 2022